Stratagene Reports Second Quarter Results; Company Takes $7.9 Million Litigation Charge and Updates 2006 Financial Guidance; Cash Position Includes $33.6 Million in Restricted and Unrestricted Cash.
Business Wire (August 08, 2006)
Permanent Link:
http://vlex.com/vid/stratagene-restricted-unrestricted-55763252
Id. vLex: VLEX-55763252
Acceda a este documento
y pruebe vLex GRATIS durante 3 días
Stratagene Reports Second Quarter Results; Company Takes $7.9 Million Litigation Charge and Updates 2006 Financial Guidance; Cash Position Includes $33.6 Million in Restricted and Unrestricted Cash.
LA JOLLA, Calif. -- Company Enters New Agreement With Major Pharmaceutical Company to Develop Sample Preparation System to Track Molecular Biomarkers
Stratagene Corporation (Nasdaq:STGN), a developer, manufacturer and marketer of specialized life science research and diagnostic products, today released financial results for the second quarter of 2006 ended June 30, 2006. For the second quarter of 2006, revenue was $23.4 million, compared with revenue of $24.9 million in the second quarter of 2005. The year-over-year revenue decrease primarily resulted from the ongoing decline in sales of legacy products associated with gene discovery and cloning systems. Partially offsetting this decline was the continued growth in sales of QPCR instruments, which were up 3.5% year-over-year and sales of allergy diagnostic products, which grew 2.5% year-over-year. "We ...Try vLex for FREE for 3 days
Access legal information from United States including:
- Constitutions
- Forms and Contracts
- Legal Books and Journals
- Case Law
- News and Business
- Regulations
- U.S. Code
Try vLex without any commitment for 3 days and see why you need it.
3
days of Free Access
If you are already a vLex customer, Access Here
